• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Xu Xiaochun converted options into 654,206 shares (SEC Form 4)

    10/2/23 8:33:42 PM ET
    $THMO
    Medical Specialities
    Industrials
    Get the next $THMO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Xu Xiaochun

    (Last) (First) (Middle)
    2711 CITRUS ROAD

    (Street)
    RANCHO CORDOVA CA 95742

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ThermoGenesis Holdings, Inc. [ THMO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    09/28/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/28/2023 C(1) 654,206 A $1.07 927,121 I Held by Boyalife Group, Inc.
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Amendment 3 to 1st Amended & Restated Revolving Credit Agr. $1.07(1) 09/28/2023 C(1) $700,000(1) 04/16/2018 12/31/2023 Common Stock 654,206 (1) $7,494,000(1) I Held by Boyalife Group, Inc.
    1. Name and Address of Reporting Person*
    Xu Xiaochun

    (Last) (First) (Middle)
    2711 CITRUS ROAD

    (Street)
    RANCHO CORDOVA CA 95742

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Boyalife Group, Inc.

    (Last) (First) (Middle)
    2453 S. ARCHER AVE.
    SUITE B

    (Street)
    CHICAGO IL 60616

    (City) (State) (Zip)
    Explanation of Responses:
    1. On September 28, 2023, Boyalife Group, Inc. converted an aggregate of $700,000 of outstanding interest under a Second Amended and Restated Convertible Promissory Note issued by Issuer in April 2018, as amended. After giving effect to the conversion, as of the date of this Form 4, there was $7,278,000 in principal and approximately $216,000 in accrued interest outstanding under the Convertible Promissory Note, all of which is convertible at a current conversion price of $1.07 per share, subject to downward adjustment in the event that the Issuer issues shares of common stock at a lower price. Boyalife Group, Inc. is 100% owned by Dr. Xiaochun Xu.
    /s/ Xiaochun Xu 10/02/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $THMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Xu Xiaochun converted options into 7,894,737 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    7/9/24 7:02:58 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun converted options into 4,113,158 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    3/19/24 2:09:52 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun sold $612,000 worth of shares (600,000 units at $1.02) (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    11/21/23 7:30:22 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    SEC Filings

    View All

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    1/6/25 5:30:21 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form NT 10-Q filed by ThermoGenesis Holdings Inc.

    NT 10-Q - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/15/24 3:53:44 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/6/24 5:20:08 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    RANCHO CORDOVA, Calif., Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023, in New York.  Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. Those interested in meeting wit

    9/6/23 8:30:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Leadership Updates

    Live Leadership Updates

    View All

    Atlantic Therapeutics Announces the Appointment of Russell Medford MD, PhD as New US-Based Chairman

    BOSTON, July 27 2022 Appointment aligns with recognized high growth potential for INNOVO® in the US.A strong endorsement for the scientific and clinical credibility of INNOVO® as an accessible treatment for Stress Urinary Incontinence (SUI).Endorses FemTech as a high potential investment category./PRNewswire/ -- Today Atlantic Therapeutics, a Galway, Ireland and Boston, USA-based MedTech innovator, announces the appointment of Russell Medford MD, PhD as Chairman. The addition of Dr Medford to the Board is a significant step to fulfill the potential of the INNOVO® brand in the large and under-served US stress urinary incontinence (SUI) market. Dr Medford is a senior healthcare and life scien

    7/27/22 7:00:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Financials

    Live finance-specific insights

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update

    Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call

    8/8/23 3:26:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    11/27/23 8:10:20 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    8/14/23 4:27:10 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    4/10/23 6:14:26 PM ET
    $THMO
    Medical Specialities
    Industrials